Chair of Medical Biotechnology, Department of Cancer Immunology, Poznan University of Medical Sciences, 8 Rokietnicka St, Poznan 60-806, Poland; Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 Garbary St, Poznan 61‑866, Poland; Doctoral School, Poznan University of Medical Sciences, 70 Bukowska St, Poznan 60-812, Poland.
Chair of Medical Biotechnology, Department of Cancer Immunology, Poznan University of Medical Sciences, 8 Rokietnicka St, Poznan 60-806, Poland; Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 Garbary St, Poznan 61‑866, Poland.
Biomed Pharmacother. 2024 Nov;180:117585. doi: 10.1016/j.biopha.2024.117585. Epub 2024 Oct 22.
Cancer remains one of the leading causes of death worldwide and poses a significant challenge to effective treatment due to its complexity. Angiogenesis, the formation of new blood vessels, is one of the cancer hallmarks and is a critical process in tumor growth and metastasis. The pivotal role of angiogenesis in cancer development has made antiangiogenic treatment a promising strategy for cancer therapy. To develop an effective therapy, it is essential to understand the basics of the physiological and tumor angiogenesis process. This review presents the primary factors related to physiological and tumor angiogenesis and the mechanisms of angiogenesis in tumors. We summarize potential molecular targets for cancer treatment by focusing on the vasculature, with the VEGF/VEGFR pathway being one of the most important and well-studied. Additionally, we present the advantages and limitations of currently used clinical protocols for cancer treatment targeting the VEGF/VEGFR pathway.
癌症仍然是全球主要死因之一，由于其复杂性，对有效治疗构成了重大挑战。血管生成，即新血管的形成，是癌症的标志之一，也是肿瘤生长和转移的关键过程。血管生成在癌症发展中的关键作用使得抗血管生成治疗成为癌症治疗的一种有前途的策略。为了开发有效的治疗方法，了解生理和肿瘤血管生成过程的基础知识是至关重要的。
本综述介绍了与生理和肿瘤血管生成相关的主要因素以及肿瘤中血管生成的机制。我们通过关注血管系统，总结了癌症治疗的潜在分子靶点，其中 VEGF/VEGFR 途径是最重要和研究最充分的途径之一。此外，我们还介绍了目前用于靶向 VEGF/VEGFR 途径治疗癌症的临床方案的优缺点。
